Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Probuphine: Formidable Hurdles Will Severely Limit Adoption
  • USA - English


News provided by

Rubenstein PR

May 27, 2016, 07:00 ET

Share this article

Share toX

Share this article

Share toX

(PRWEB) May 27, 2016 -- The Food & Drug Administration (FDA) announced today its approval of Probuphine, an implantable form of buprenorphine, a medication used to treat opiate addiction. It works by reducing cravings and withdrawal symptoms.

“Probuphine could positively impact medication compliance and help individuals seeking longer-term treatment for Opiate Use Disorder,” says Dr. Indra Cidambi, leading Addiction Expert and Medical Director at Center for Network Therapy, New Jersey’s first licensed outpatient detox facility. “However, implementation challenges will severely limit the adoption of Probuphine.”

Of the roughly 2.5 million Americans addicted to opiates, it is estimated about 20% are addicted to illegal opioids, such as heroin, and the other 80% are addicted to prescription opioids, such as oxycodone, hydrocodone, methadone, hydromorphone and codeine. Less than half of these individuals receive medication-assisted treatment to address their substance use disorder, suggesting a vast market.

“Probuphine offers important benefits not currently provided by other forms of buprenorphine. For example, since Probuphine is in implantable form, the medication is gradually released into the blood stream, helping medication compliance,” says Dr. Cidambi. “But, the processes related to dispensation of the medication make it impractical.”

Dr. Cidambi shares six reasons why she believes Probuphine will flop:

1. Efficacy Not A Given: “Probuphine is recommended for people requiring 8mg of buprenorphine or less a day. If this dosage proves to be less than one needs, it’s possible that an individual in recovery may seek opiates on the streets in order to satisfy cravings or avoid withdrawal,” said Dr. Cidambi. “Also, Probuphine will ‘incentivize’ patients not to attend counseling in conjunction with medication assisted treatment, as they have to see their doctor only once every six months. This may inhibit their recovery as they ignore the lifestyle changes they need to make and rely solely on medication,” says Dr. Cidambi.

2. Co-Abuse of “Benzos” Could Prove Dangerous: If individuals implanted by Probuphine co-abuse other class of drugs, such as benzodiazepines, the effect is the same as using opiates and benzodizapines together – i.e. increased risk of respiratory depression. As per NCBI, co-abuse of benzodiazepines and opiates increased by 570% from 2000 to 2010. So, if these individuals do not participate in counseling they are unlikely to be monitored for abuse of other substances and this could prove dangerous.

3. Prescribers Lack Surgical Skills: “Probuphine requires a physician with some level of surgical skill to implant the medication under the skin,” says Dr. Cidambi. Currently family/general practitioners, Doctors of Osteopathy, internists and psychiatrists write nearly three-fourths of buprenorphine prescriptions, and only a small percent of prescriptions is prescribed by doctors with training in surgery. “While Probuphine’s manufacturer expects doctors prescribing buprenorphine to undergo training to learn to implant Probuphine, it is hard to envision this happening - a physician’s office may not be set up to perform a surgical procedure; a physician may not want to deal with complications resulting from such procedures; and participating physician’s malpractice insurance rates may be negatively impacted due to inclusion of surgical procedures,” added Dr. Cidambi.

4. Divided Care Cumbersome: “If enough current prescribers of Buprenorphine do not participate in the Probuphine implant program (even if they participate in the prescriber program), it would lead to divided care,” says Dr. Cidambi. “In that scenario, the prescriber (likely an addiction specialist) would have to be present when the surgeon (or equivalent) performs the procedure, which would create logistical headaches. Also, who is responsible for the patient? The doctor who prescribes the medication or the doctor who implants it? And who provides follow-up care?” asks Dr. Cidambi.

5. Implant Removal Difficult: A study showed that only seven out of 15 specialists who participated in the trial were able to remove all four implants successfully and the other eight followed ‘proper procedure.’ “What this means is that the eight did what was recommended when they could not take the implant out. The problem seemed to be that the implant was not palpable (the physician could not feel the implant through the skin). So, they would have to send the patient for imaging in order to locate the implant. This, obviously becomes unwieldy,” says Dr. Cidambi.

6. Unpalatable Accounting Requirement: Probuphine is to be distributed under a ‘closed distribution system,’ which means that the manufacturer will ship the product directly to buprenorphine providers trained to implant the drug. “The providers would have to store the medication (a controlled substance) in their offices and then implement an inventory and accounting system for the controlled substance. The responsibility of storing the medication and additional paperwork will be a strong deterrent to providing the implant,” observes Dr. Cidambi.

For more information on substance abuse dependency, addiction and treatment, please go to http://www.recoveryCNT.com.

About Dr. Indra Cidambi
Indra Cidambi, M.D., Medical Director, Center for Network Therapy, is recognized as a leading expert and pioneer in the field of Addiction Medicine. Under her leadership the Center for Network Therapy started New Jersey’s first state licensed Ambulatory (Outpatient) Detoxification program for all substances nearly three years ago. Dr. Cidambi is Board Certified in General Psychiatry and double Board Certified in Addiction Medicine (ABAM, ABPN). She is fluent in five languages, including Russian.

About Center for Network Therapy
Center for Network Therapy (CNT) was the first facility in New Jersey to be licensed to provide Ambulatory (Outpatient) Detoxification Services for all substances of abuse – alcohol, anesthetics, benzodiazepines, opiates and other substances of abuse. Led by a Board Certified Addiction Psychiatrist, Indra Cidambi, M.D., experienced physicians and nurses closely monitor each patient’s progress. With CNT’s superior client care and high quality treatment, Dr. Cidambi and her clinical team have successfully detoxed over 600 patients in nearly three years.

Marisa Amador, Rubenstein PR, +1 (212) 843-9329, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.